[2026-07-31] Endocrine extension #1 — carbohydrate-insulin model (CIM), both poles

  • Searched: WebSearch/Google — isocaloric low carbohydrate high fat diet body fat metabolic ward meta-analysis energy expenditure Hall
  • Filters: none; design limit = SR/MA + metabolic-ward RCT
  • Found / screened: ~8 / 2
  • Included: Hall - Obesity Energetics Diet Composition 2017 (ACQUIRE, manual — refuting-pole SR/MA)
  • Excluded (notable): Hall 2015 Cell Metab — DEFER (single ward RCT, subsumed by the SR/MA)
  • Notes: CIM poles already held/staged (Ludwig, Hall-EBM, Ebbeling, Feinman, Hall-UPF); tension near-closure, not a gap. gold-gate: the new item is a high-tier SR/MA.

[2026-07-31] Endocrine extension #2 — adiposity->testosterone->muscle/sarcopenia

  • Searched: WebSearch/PubMed — weight loss testosterone obesity hypogonadism systematic review meta-analysis Corona; testosterone therapy cardiovascular outcomes TRAVERSE trial hypogonadism randomized; testosterone treatment lean body mass muscle strength physical function older men meta-analysis
  • Filters: none; design limit = SR/MA/umbrella + landmark RCT
  • Found / screened: ~12 / 5
  • Included: Corona - Weight Loss Obesity Hypogonadism Meta-Analysis 2013; Lopez Hilario - Androgen Musculoskeletal Umbrella 2026; Lincoff - TRAVERSE Testosterone Cardiovascular Safety 2023; Snyder - Testosterone Treatment Fractures 2024 (all ACQUIRE, manual)
  • Excluded (notable): Skinner 2018 GeroScience + Karger strength MA — DEFER (subsumed by the umbrella)
  • Notes: framed via muscle/function/fracture, NOT T-level. Snyder-2024 = hard-outcome HARM inverting the BMD surrogate (high marginal value). Umbrella also surfaces exercise > T for strength (Layer-1).

[2026-07-31] Endocrine extension #3 — menopause -> cardiometabolic + bone + body-composition; HRT

  • Searched: WebSearch — menopause hormone therapy guideline NAMS position statement 2022 cardiovascular bone; NICE menopause guideline NG23 2024 diagnosis management HRT; Women's Health Initiative estrogen progestin principal results Rossouw ... 2002; menopause transition visceral fat body composition change longitudinal SWAN meta-analysis
  • Filters: none; design limit = guideline + landmark RCT + MA
  • Found / screened: ~14 / 5
  • Included (FETCHED to inbox): NAMS - Hormone Therapy Position Statement 2022; NICE - Menopause Identification Management NG23 2024; Rossouw - WHI Estrogen Progestin Principal Results 2002. Included (manual): Ambikairajah - Fat Mass Changes Menopause Meta-Analysis 2019
  • Excluded (notable): Greendale/SWAN 2019 JCI Insight — DEFER (cohort, subsumed by the Ambikairajah MA)
  • Notes: two independent guidance families (NAMS + NICE) => the guidance-SET null; WHI = the HT hard-outcome RCT. All gold except the body-comp MA (high).

[2026-07-31] Endocrine extension #4 — cortisol / HPA -> visceral adiposity; MBSR on physical outcomes

  • Searched: WebSearch — mindfulness stress reduction blood pressure randomized controlled trials meta-analysis
  • Filters: none; design limit = SR/MA of RCTs; kept deliberately thin (attention-is-an-anti-signal)
  • Found / screened: ~7 / 3
  • Included (FETCHED to inbox): Chen - Mindfulness Prehypertension Hypertension Meta-Analysis 2024
  • Excluded (notable): Conversano 2021 (E-corroboration) — DEFER; Loucks MB-BP 2023 — REJECT (single dev trial); cortisol-level papers — REJECT (surrogate)
  • Notes: admit MBI/MBSR -> BP (physical outcome), keep peripheral; cortisol->visceral-fat woven as mechanism only.

[2026-07-31] Endocrine extension #5 — adipose tissue as an endocrine organ (mechanism)

  • Searched: WebSearch — adipose tissue endocrine organ review adipokines insulin resistance cardiometabolic
  • Filters: none
  • Found / screened: ~9 / 3
  • Included: none
  • Excluded (notable): Kershaw & Flier 2004 JCEM — DEFER (mechanism-only, optional); all adipokine-level reviews — REJECT (surrogate + narrative below gold)
  • Notes: KEYSTONE GAP (type-G) — no patient-important gold keystone; genuinely mechanism-only, NOT filled with a surrogate substitute. Decision content lives on the visceral-adiposity outcome pages.

[2026-07-31] Endocrine extension #6 — sleep and metabolic/appetite hormones -> weight + glycaemia

  • Searched: WebSearch — sleep restriction energy intake weight systematic review meta-analysis; sleep duration type 2 diabetes incidence dose-response meta-analysis prospective
  • Filters: none; design limit = SR/MA (prospective) + RCT MA
  • Found / screened: ~10 / 4
  • Included: Shan - Sleep Duration Type 2 Diabetes Meta-Analysis 2015 (gold); Capers - Sleep Duration Adiposity Energy Balance Meta-Analysis 2015 (both ACQUIRE, manual)
  • Excluded (notable): Al Khatib 2017 — DEFER (subsumed by Capers); sleep->ghrelin/leptin MAs — REJECT (surrogate + inconsistent)
  • Notes: Shan reaches T2D incidence (patient-important) + intersects the held U-shaped-artifact and Cappuccio sleep-mortality; Capers = the causal (RCT) weight arm.

[2026-07-31] Endocrine extension #7 — hunger/appetite regulation (leptin/ghrelin/GLP-1/PYY/CCK)

  • Searched: WebSearch — gut hormones appetite regulation leptin ghrelin GLP-1 PYY body weight review satiety
  • Filters: none
  • Found / screened: ~8 / 2
  • Included: none (Sumithran 2011 + GLP-1 cluster already HELD — the patient-important anchors)
  • Excluded (notable): gut-hormone/appetite narrative reviews — REJECT (surrogate hormone-level + narrative below gold)
  • Notes: KEYSTONE GAP (type-G) — no gold SR/MA reaching a patient-important outcome via endogenous appetite hormones distinct from Sumithran; NOT filled. Weave as mechanism linking Sumithran <-> GLP-1 <-> adherence.